A Multicenter Phase 1, Open-Label Study of DCC-3014 to Assess the
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients
with Advanced Malignancies
This study is being done to test the good and bad effects of DCC-3014-01-001 in patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, and Chronic Lymphoblastic Leukemia.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Lymphoblastic Leukemia (ALL), and Chronic Lymphoblastic Leukemia (CLL)
1. Men and women 18 years or older, except for patients with ALL who can be 16 years or older
2. Have been diagnosed with AML, MDS, ALL, or CLL, and your disease has not responded to previous treatment
3. Adequate organ function
4. Other criteria apply
16 - n/a
Healthy Volunteers Needed
Duration of Participation
Participants will receive the study drug as long as their cancer does not get worse and they do not develop side effects that they cannot tolerate. 30 days after last dose of study drug, participants will have a follow-up visit.
Knight Clinical Trials Information Line
Deciphera Pharmaceuticals, LLC